Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR18034 Adductor Canal Block for Postoperative Pain in TKA
NCT05561309Phase 2Active, not recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Oct 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bupivacaine liposome in postoperative pain (6 arms), sponsored by Hengrui Therapeutics. Primary endpoint: AUC0-72 of the NRS-R pain intensity scores. Started Oct 2022; status: active, not recruiting.
02
Drugs
bupivacaine liposome
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT05561309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05561309.